Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Diamedica Therapeutics ( (DMAC) ) is now available.
DiaMedica Therapeutics Inc. held its 2026 Annual General Meeting of Shareholders on May 20, 2026, where investors re-elected seven incumbent directors to the board and reaffirmed the company’s governance continuity. Shareholders also ratified Baker Tilly US, LLP as independent auditor for the 2026 fiscal year, signaling support for the firm’s existing financial oversight framework.
In advisory voting, shareholders approved the company’s executive compensation program, indicating broad backing for current leadership’s pay structure. They further endorsed an amendment to the 2019 Omnibus Incentive Plan to add 3,500,000 shares, expanding the equity pool and potentially enhancing DiaMedica’s ability to attract and retain key talent as it advances its development pipeline.
The most recent analyst rating on (DMAC) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Diamedica Therapeutics stock, see the DMAC Stock Forecast page.
Spark’s Take on DMAC Stock
According to Spark, TipRanks’ AI Analyst, DMAC is a Neutral.
The score is held back primarily by weak financial performance (no revenue with widening losses and sustained cash burn). The earnings call provides meaningful support due to strong clinical progress and a stated cash runway into 2027, but technicals remain bearish and valuation offers limited help given ongoing losses and no dividend.
To see Spark’s full report on DMAC stock, click here.
More about Diamedica Therapeutics
DiaMedica Therapeutics Inc. operates in the biopharmaceutical sector, focusing on the development of therapeutic candidates, particularly in neurology and related indications. The company targets unmet medical needs with clinical-stage programs, positioning itself within the innovative drug development market for serious and underserved conditions.
Average Trading Volume: 196,820
Technical Sentiment Signal: Sell
Current Market Cap: $308.2M
For an in-depth examination of DMAC stock, go to TipRanks’ Overview page.